东西方肝癌的分析比较文档ppt课件.pptVIP

Comparative Analyses of Hepatocellular Carcinoma between East and West ─ Implication on the design of clinical trials ;Geographic and ethnic factors become important in the era of molecular targeted therapy for cancers;Asian (n=342);EGFR mutation rates in each subgroup;Liver Cancer in the World ;;SorafenibMedian: 46.3 weeks (10.7 mo)(95% CI: 40.9, 57.9);Comparison of Tx(-) Control Arms;Randomized trials - octreotide vs placebo ;Study Schema of SHARP and AP Studies;Phase III SHARP and Asia-Pacific Overall Survival;Asia-Pacific Liver Cancer Study vs SHARP:Baseline Patient Characteristics;Llovet JM et al. Lancet. 2003; 362:1907-1917.;Meta-analysis of Phase III clinical Trials of HCC;Meta-regression: Predictors of survival of the control group patients (1);HCC;Makuuchi M. et al, Hepatology Research 2007;;Etiology of HCC— Distinct Geographic Distribution;Is HBV-related HCC a more aggressive tumor ? Is HBV-related HCC associated with molecular changes which affect molecular therapy ?;HCC ─ East vs West;HBV vs. HCV HCCItalian Liver Cancer group;HBV vs. HCV HCC in NTUHSurvival for patients with advanced ds.;Is HBV-related HCC a more aggressive tumor ? Is HBV-related HCC associated with molecular changes that will affect molecular therapy ?;HBV- vs. HCV-associated HCC — Genomics and Proteomics;Viral Proteins And Signal Transduction Pathways;Transcriptome classification of HCC;Molecular Epidemiology of HBV — not all HBVs are the same;Sorafenib phase II HCC studyHCV- vs. HBV-related HCC;Sub-group analysis of the SHARP trial;Thalidomide phase II HCC studyHCV- vs. HBV-related HCC;;Phase II study of bevacizumab + capecitabine in patients with advanced/metastatic hepatocellular carcinoma;Median OS: 5.9 M (95% CI: 4.1-9.7);Worldwide, multicenter, open-label, 1,200 pts with advanced HCC;Conclusion;Comparative Analyses of Hepatocellular Carcinoma between East and West ─ Implication on the design of clinical trials ;purines and pyrimidines;Chemotherapy;Geographic Differen